Last reviewed · How we verify
Group 3: Liposomal amphotericin B
Liposomal amphotericin B binds to ergosterol in fungal cell membranes, disrupting membrane integrity and causing cell death.
Liposomal amphotericin B binds to ergosterol in fungal cell membranes, disrupting membrane integrity and causing cell death. Used for Invasive fungal infections (e.g., candidiasis, aspergillosis, cryptococcosis), Amphotericin B-resistant fungal infections.
At a glance
| Generic name | Group 3: Liposomal amphotericin B |
|---|---|
| Sponsor | Fundacion Nacional de Dermatologia |
| Drug class | Polyene antifungal |
| Target | Ergosterol |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Amphotericin B is a polyene antifungal that inserts into the fungal cell membrane and forms pores, leading to leakage of cellular contents and fungal cell lysis. The liposomal formulation reduces toxicity to human cells by preferentially delivering the drug to fungal cells and infected tissues while minimizing exposure to healthy host cells.
Approved indications
- Invasive fungal infections (e.g., candidiasis, aspergillosis, cryptococcosis)
- Amphotericin B-resistant fungal infections
Common side effects
- Nephrotoxicity
- Infusion-related reactions (fever, chills, rigors)
- Hypokalemia
- Anemia
- Hypomagnesemia
Key clinical trials
- Liposomal Amphotericin B in Invasive Aspergillosis With Hepatic Dysfunction (NA)
- Platform Trial For Cryptococcal Meningitis (PHASE2, PHASE3)
- Liposomal Amphotericin B Plus Posaconazole/Isavuconazole for Mucormycosis in Hematologic Malignancies: Efficacy and Safety
- Optimizing the Dose of Flucytosine for the Treatment of Cryptococcal Meningitis (PHASE2)
- Liposomal Amphotericin B and Isavuconazole/Posaconazole in Br-IFD（ Breakthrough Invasive Fungal Disease） in Patients With Malignant Hematological Diseases
- Anti-fungal Strategies in Acute-on-Chronic Liver Failure Patients (NA)
- Efficacy and Safety of High-dose Liposomal Amphotericin B for Disseminated Histoplasmosis in AIDS (PHASE3)
- Treatment of Mucosal Bolivian Leishmaniasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: